METHODS OF TREATING CORONAVIRUS INFECTIONS

1 . A method of treating a coronavirus infection in a subject comprising administering to the subject dantrolene or a pharmaceutically acceptable salt thereof or by administering a dantrolene prodrug or a pharmaceutically acceptable salt thereof.

2 . The method of claim 1 , comprising administering dantrolene to the subject.

3 . The method of claim 1 , comprising administering a pharmaceutically acceptable salt of dantrolene to the subject.

4 . The method of claim 1 , comprising administering dantrolene sodium to the subject.

5 . The method of claim 1 , wherein the administration results in at least a 1-point decrease in the subject's WHO Ordinal Scale score, as compared to baseline.

6 . The method of claim 1 , wherein the administration results in an improvement in the subject's Sequential Organ Failure Assessment daily score, as compared to baseline.

7 . The method of claim 1 , wherein the administration results in a reduction of time to normalization of fever in the subject, as compared to the amount of time to normalization of fever in a control subject.

8 . The method of claim 1 , wherein the administration results in a reduction of time to normalization of oxygen saturation in the subject, as compared to the amount of time to normalization of oxygen saturation in a control subject

9 . A method for inhibiting replication of a coronavirus in a subject comprising administering to the subject dantrolene, or a pharmaceutically acceptable salt thereof or by administering a dantrolene prodrug or a pharmaceutically acceptable salt thereof.

10 . The method of claim 9 , comprising administering dantrolene to the subject.

11 . The method of claim 9 , comprising administering a pharmaceutically acceptable salt of dantrolene to the subject.

12 . The method of claim 9 , comprising administering dantrolene sodium to the subject.

13 . A method for inhibiting replication of a coronavirus in a host cell, for inhibiting entry of a coronavirus into a host cell, for inhibiting a coronavirus virion maturation in a host cell, or for inhibiting release of a coronavirus from a host cell comprising administering to the host cell dantrolene, or a pharmaceutically acceptable salt thereof or by administering a dantrolene prodrug or a pharmaceutically acceptable salt thereof.

14 . The method of claim 13 , comprising administering dantrolene to the host cell.

15 . The method of claim 13 , comprising administering a pharmaceutically acceptable salt of dantrolene to the host cell.

16 . The method of claim 13 , comprising administering dantrolene sodium to the host cell.

17 . A method for reducing the infectivity of a coronavirus by administering to a host cell dantrolene, or a pharmaceutically acceptable salt thereof or by administering a dantrolene prodrug or a pharmaceutically acceptable salt thereof.

18 . The method of claim 17 , comprising administering dantrolene to the host cell.

19 . The method of claim 17 , comprising administering a pharmaceutically acceptable salt of dantrolene to the host cell.

20 . The method of claim 17 , comprising administering dantrolene sodium to the host cell.